Harikrishna Nakshastri, PhD, on Characterizing Early Oncogenesis in Breast Cancer

Video

The professor of breast cancer research at Indiana University discussed new research with the TONSL gene from Indiana University.

“What happens very early, when the cells first encounter these genomic aberrations that make them immortal and not die off after 10 to 15 cycles of division? For many years, people have not been able to [answer that question], mainly because we had no way to grow enough primary cells with allof them dying. So now, with the tissue bank that we have, more than 6000 healthy women donated their breast tissue for research purpose. We collect common normal tissue bank at Indiana University Simon Comprehensive Cancer Center. From that we came up with a method where we can take a core biopsy, grow the cells out of them, and then immortalize them.”

Recent research from the Indiana University School of Medicine has identified the TONSL gene as an immortalizing oncogene and therefore a potential therapeutic target.This research was presented at the American Associated for Cancer Research (AACR) Annual Meeting 2023, held April 14-19 in Orlando, Florida, by Harikrishna Nakshastri, PhD, Marian J. Morrison Professor of Breast Cancer Research at Indiana University School of Medicine.

CGTLive’s sister site, OncLive, spoke with Nakshastri to learn more about the research him and his team conducted with early oncogenesis in cell lines and how they identified the TONSL gene as an immortalizing oncogene. He discussed the progress that has been made in understanding the genomics of cancer in the recent past but stressed that many questions remain to be answered about the early phases of oncogenesis. He credited IU’s tissue bank and the thousands of women that have donated breast tissue to help research these questions.

REFERENCE
Khatpe AS, Dirks R, Bhat-Nakshastri P, et al. TONSL is an immortalizing oncogene of the chromosome 8q24.3 amplicon and new therapeutic target in breast cancer. Presented at: AACR Annual Meeting 2023. Abstract 5458.
Recent Videos
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Related Content
© 2025 MJH Life Sciences

All rights reserved.